**Spotlight on the colon**

1 – 5 December 2019, St.Gallen, Switzerland

---

**Sunday, 1 Dec. 2019**

MASTERCLASS

**09.00**
When the appendix plays nasty: intraoperative surprises, immediate solutions, and long-term treatment options

Justin Davies, Cambridge, UK

**09.40**
All the secrets of the pelvic floor – common disorders and proven solutions

Julie Cornish, Cardiff, UK

---

**Monday, 2 Dec. 2019**

SCIENTIFIC PROGRAMME

**09.45**
Opening and welcome

Jochen Lange, St.Gallen, CH

**10.00**
Pathophysiology and non-operative management of symptomatic uncomplicated diverticular disease

Robin Spiller, Nottingham, UK

**10.30**
Surgery of acute diverticulitis – evidence, eminence and real life

Willem Bemelman, Amsterdam, NL

**11.00**
Management of atypical diverticulitis

Dieter Hahnloser, Lausanne, CH

---

**Tuesday, 3 Dec. 2019**

**09.00**
Robotic-assisted versus conventional laparoscopic surgery for rectal cancer

Aamad Parvaz, Poole, UK

**09.30**
Robotic multivisceral resection

Paris Tekkis, London, UK

---

**Wednesday, 4 Dec. 2019**

**09.00**
Is anastomotic leak an infectious disease

Rohan O’Connell, Dublin, IE

**09.30**
Is it time to invest in robotic surgery?

Antonino Spinelli, Milan, IT

---

**Thursday, 5 Dec. 2019**

**09.00**
Management of locoregionally advanced colon cancer

Torbjorn Holm, Stockholm, SE

**09.30**
Rountable

Herard Abcarian, Chicago, US

Bill Heald, Basingstoke, UK

---

**Information & Registration**

[www.colorectalsurgery.eu](http://www.colorectalsurgery.eu)

The publication of this advertisement does not constitute endorsement by the society, publisher, or Editors, and is unrelated to the content that follows.
Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer

E. Versteijne1, J. A. Vogel2, M. G. Besselink3, O. R. C. Busch2, J. W. Wilmink3, J. G. Daams4, C. H. J. van Eijck5, B. Groot Koerkamp5, C. R. N. Rasch1 and G. van Tienhoven1, on behalf of the Dutch Pancreatic Cancer Group

Departments of 1Radiation Oncology, 2Surgery and 3Medical Oncology, Cancer Centre Amsterdam, Academic Medical Centre, and 4Medical Library, Academic Medical Centre, Amsterdam, and 5Department of Surgery, Erasmus Medical Centre, Erasmus University Rotterdam, Rotterdam, The Netherlands

Correspondence to: Dr E. Versteijne, Department of Radiation Oncology, Cancer Centre Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands (e-mail: e.versteijne@amc.uva.nl)

Background: Studies comparing upfront surgery with neoadjuvant treatment in pancreatic cancer may report only patients who underwent resection and so survival will be skewed. The aim of this study was to report survival by intention to treat in a comparison of upfront surgery versus neoadjuvant treatment in resectable or borderline resectable pancreatic cancer.

Methods: MEDLINE, Embase and the Cochrane Library were searched for studies reporting median overall survival by intention to treat in patients with resectable or borderline resectable pancreatic cancer treated with or without neoadjuvant treatment. Secondary outcomes included overall and R0 resection rate, pathological lymph node rate, reasons for unresectability and toxicity of neoadjuvant treatment.

Results: In total, 38 studies were included with 3484 patients, of whom 1738 (49.9 per cent) had neoadjuvant treatment. The weighted median overall survival by intention to treat was 18.8 months for neoadjuvant treatment and 14.8 months for upfront surgery; the difference was larger among patients whose tumours were resected (26.1 versus 15.0 months respectively). The overall resection rate was lower with neoadjuvant treatment than with upfront surgery (66.0 versus 81.3 per cent; P < 0.001), but the R0 rate was higher (86.8 (95 per cent c.i. 84.6 to 88.7) versus 66.9 (64.2 to 69.6) per cent; P < 0.001). Reported by intention to treat, the R0 rates were 58.0 and 54.9 per cent respectively (P = 0.088). The pathological lymph node rate was 43.8 per cent after neoadjuvant therapy and 64.8 per cent in the upfront surgery group (P < 0.001). Toxicity of at least grade III was reported in up to 64 per cent of the patients.

Conclusion: Neoadjuvant treatment appears to improve overall survival by intention to treat, despite lower overall resection rates for resectable or borderline resectable pancreatic cancer.

PROSPERO registration number: CRD42016049374.

Paper accepted 7 March 2018
Published online 30 April 2018 in Wiley Online Library (www.bjs.co.uk). DOI: 10.1002/bjs.10870

Introduction

Pancreatic cancer is recognized as having an overall poor prognosis and low resection rate. Long-term survival remains limited even after tumour resection. Surgical resection with adjuvant chemotherapy is the current standard of care1. Recent trials1,2 have reported improved median overall survival to 24.5–28 months with adjuvant treatment. However, these trials did not report how many eligible patients were fit enough to be randomized to receive adjuvant chemotherapy. Currently, the strongest predictors of survival include surgery with curative intent, early-stage disease and complete (R0) resection. None of these predictors are influenced by adjuvant treatment.

In patients with resectable pancreatic cancer, a recent study3 of Surveillance, Epidemiology, and End Results (SEER) data from nearly 4000 patients suggested a survival benefit with neoadjuvant radiotherapy with or without chemotherapy over upfront surgery with or without adjuvant treatment. However, RCTs of neoadjuvant treatment compared with upfront surgery are lacking.
Non-randomized studies evaluating neoadjuvant treatment of patients with either borderline resectable or upfront resectable pancreatic cancer often suffer from selection bias because they report survival data only for patients who eventually underwent pancreatic resection. Patients with disease progression or severe toxicity who did not undergo resection are often excluded. Moreover, patients found to have metastatic or unresectable disease at exploratory surgery are also excluded.

The aim of this study was to perform a systematic review of studies comparing median overall survival of patients who underwent upfront surgery versus those who underwent neoadjuvant treatment in intention-to-treat analyses.

Methods

The systematic review was performed according to the PRISMA guidelines. The review was registered at PROSPERO (registration number: CRD42016049374).

Search strategy

The literature was reviewed systematically by searching in MEDLINE, Embase and the Cochrane Library for studies published between 1 January 2000 and 6 December 2016. The search strategy included the following domains of Medical Subject Heading (MeSH) terms: ‘pancreatic neoplasm’, ‘survival’, ‘mortality’ and ‘survival analysis’; these were combined with ‘AND’ or ‘OR’. No language restrictions were used. For the MEDLINE and Embase searches, a McMaster specific prognosis filter was applied, completed with the authors’ own terminology to cover the survival concept of the search strategy. A full description of the search is available in Appendix S1 (supporting information).

Eligibility

Studies including patients with resectable or borderline resectable pancreatic cancer, either treated by upfront surgery or with neoadjuvant treatment, and reporting median overall survival by intention to treat (based on the initial treatment assignment and not on the treatment eventually received) were included. No selection was made based on adjuvant treatment. Excluded were review articles, notes, letters, case reports (5 or fewer patients), animal studies, studies that did not report median overall survival by intention to treat, and studies that reported on only specific groups of patients (for example, those with renal impairment, older than 70 years, or with poor performance status). Studies that did not report median overall survival separately for resectable and borderline resectable pancreatic tumours were also excluded.

Study selection

Two authors screened the titles and abstracts independently for eligibility. After the first two rounds of screening, full-text screening was carried out. Disagreements were resolved by discussion and consensus achieved. Primary and secondary outcomes were extracted from the full text. If studies had an overlapping cohort, the most recent study was included.

Methodological quality

All studies were assessed for risk of bias using a standard list of 11 potential risks of bias, based on the Oxford Centre for Evidence-Based Medicine (CEBM) Critical Appraisal Skills Programme checklists for randomized trials and observational cohort studies, and the Cochrane Collaboration’s tool for assessing risk of bias. All studies were graded according to the Oxford CEBM levels of evidence.

Outcome measures

The primary outcome, median overall survival, was extracted from the included articles. Data on numbers of patients with (borderline) resectable pancreatic cancer, resectability criteria (for example, those of the National Comprehensive Cancer Network (NCCN) and American Hepato-Pancreato-Biliary Association (AHPBA)), and types of neoadjuvant treatment and adjuvant treatment were obtained. Secondary outcomes were: resection rate, completeness of resection (R0 resection rate, only for patients undergoing resection), pathological lymph node rate, reasons for unresectability, and toxicity of at least grade III after neoadjuvant treatment.

Statistical analyses

The weighted median overall survival was calculated for the studies reporting this information for groups with and without neoadjuvant treatment. The weighted estimate of median survival ($m_p$) of both groups was derived by the formula used by Gillen and colleagues in a previous systematic review:

$$m_p = \left( \sum_{i=1}^{k} \frac{w_i}{m_i} \right)^{-1}$$

where $m_i$ denotes the median survival in a study population $i$ (with $i$ ranging from 1 to $k$, where $k$ is the number of included studies) and $w_i$ refers to a study-specific weight function. The number of study participants (divided by
Records identified through database searching \( n = 18828 \)

Additional records identified through other sources \( n = 0 \)

Records screened \( n = 1940 \)

Records screened after duplicates removed \( n = 14502 \)

Records excluded after title screening \( n = 12562 \)

Record excluded after abstract screening \( n = 1818 \)

Full-text articles excluded \( n = 84 \)
- Not by intention to treat \( n = 16 \)
- No full text available \( n = 14 \)
- Did not meet inclusion criteria \( n = 13 \)
- Outcome not reported \( n = 18 \)
- Full text not available in English \( n = 1 \)
- Results updated in included studies \( n = 4 \)
- Overlapping data \( n = 10 \)
- Outcome not reported separately for resectable and borderline resectable tumours \( n = 8 \)

Studies included in qualitative synthesis \( n = 38 \)

Studies included in quantitative synthesis (meta-analysis) \( n = 38 \)

**Fig. 1** PRISMA flow chart showing selection of articles for review

the total number of evaluable patients) was used as the weight.

The overall resection rate and the R0 rate for both groups were also calculated. The R0 rate was calculated for all patients and also for those who actually underwent resection of the pancreatic cancer. For both the overall resection rate and the R0 rate, the 95 per cent confidence interval was calculated using a proportion calculator\(^{14}\). The significance of differences in proportions was assessed by means of two-tailed Fisher’s exact test, with a significance level \( \alpha = 0.050 \), using SPSS® version 22.0.0.2 (IBM, Armonk, New York, USA).

**Results**

A total of 18828 records were identified, of which 122 screened were fully. Finally, 38 studies\(^{11–52}\) were included, with 3484 patients (Fig. 1). Study characteristics are summarized in Tables 1 and 2. Three RCTs, nine phase I or II trials, 12 prospective cohort studies and 14 retrospective cohort studies were included. The range of median age was 61.9–69.0 years in the upfront surgery group and 59–73 years in the neoadjuvant group (Tables 3 and 4). Overall, neoadjuvant treatment was administered to 1723 of 1738 patients (99.1 per cent). All studies used at least chemotherapy as neoadjuvant treatment, usually including gemcitabine (26 of 35 studies). Radiotherapy was given as part of the neoadjuvant treatment in 29 of 35 studies. No study used radiotherapy as the sole neoadjuvant treatment. The radiation dose ranged from 30 to 54 Gy.

Adjuvant therapy was initiated in ten of 12 upfront surgery studies, and 68.6 per cent of patients who underwent resection started adjuvant treatment. In the neoadjuvant treatment group, adjuvant therapy was initiated in 18 of 35 studies, and 31 per cent of patients who had resection of the pancreatic tumour started adjuvant therapy. Fewer studies reported the numbers of patients who completed adjuvant therapy (Tables 1 and 2).

**Methodological quality**

Results of the methodological quality assessment of all studies are reported in Tables S1–S3 (supporting information). Most studies were retrospective (14) or
### Table 1: Characteristics of 12 included studies that reported median overall survival after upfront surgery

| Reference                  | No. of patients | Country      | Study design | Tumour | R0 criteria (mm)* | Adjuvant treatment initiated (%) | Adjuvant treatment completed (%) |
|----------------------------|-----------------|--------------|--------------|--------|------------------|----------------------------------|----------------------------------|
| Casadei et al.15           | 20              | Italy        | RCT          | R      | > 1              | 22                               | n.r.                             |
| Golcher et al.16           | 33              | Germany      | RCT          | R      | n.s.             | 44                               | n.r.                             |
| Bao et al.17               | 78              | USA          | Prospective  | R      | n.s.             | 78                               | n.r.                             |
| Raptis et al.18            | 102             | UK           | Prospective  | R      | n.r.             | n.r.                             | n.r.                             |
| Tzeng et al.19             | 52              | USA          | Prospective  | R      | n.s.             | n.r.                             | 60                               |
| Fujii et al.20             | 71              | Japan        | Prospective  | BR     | > 1              | 100                              | 42                               |
| Fujii et al.21             | 233             | Japan        | Prospective  | R      | > 1              | 69                               | 45-6                             |
| Barbier et al.22           | 86              | France       | Retrospective| R      | > 1              | 58                               | n.r.                             |
| Papalevoza et al.23        | 92              | Japan        | Retrospective| R      | n.s.             | Adjuvant CRT: 66                 | n.r.                             |
| Kato et al.24              | 624             | Japan        | Retrospective| BR     | n.s.             | Adjuvant CT only: 69-9           | 76                               |
| Hiromi et al.25            | 331             | Japan        | Retrospective| R+BR   | 0                | 48                               | n.r.                             |
| Murakami et al.26          | 25              | Japan        | Retrospective| BR     | n.s.             | 48                               | n.r.                             |

*Definition of R0: > 1, more than 1 mm clearance from each margin; 0, no cancer cells along any margin. | Among patients who underwent resection of pancreatic cancer. R, resectable; n.r., not reported; n.s., not specified; prospective, prospective cohort study; BR, borderline resectable; retrospective, retrospective cohort study; CRT, chemoradiotherapy; CT, chemotherapy; BR-A, borderline resectable with arterial involvement.

### Table 2: Characteristics of the 35 included studies that report median overall survival after neoadjuvant treatment

| Reference                  | No. of patients | Country      | Study design | Tumour | R0 criteria (mm)* | Neoadjuvant treatment initiated (%) | Neoadjuvant treatment completed (%) |
|----------------------------|-----------------|--------------|--------------|--------|------------------|-------------------------------------|-------------------------------------|
| Palmer et al.27            | 50              | UK           | RCT          | R      | n.s.             | CT                                 | n.r.                                |
| Casadei et al.15           | 18              | Italy        | RCT          | R      | > 1              | CRT                                | 75                                 |
| Golcher et al.16           | 33              | Germany      | RCT          | R      | n.s.             | CRT                                | 37                                 |
| Evans et al.28             | 86              | USA          | Phase II     | R      | 0                | CRT                                | n.r.                                |
| Heinrich et al.29          | 28              | Switzerland  | Phase II     | R      | n.s.             | CT                                 | n.r.                                |
| Le Scodan et al.30         | 41              | France       | Phase II     | R      | 0                | CRT                                | n.r.                                |
| Turri et al.31             | 34              | France       | Phase II     | R      | 0                | CRT                                | n.r.                                |
| Small et al.32             | 17              | USA          | Phase II     | R+BR   | n.s.             | CRT                                | n.r.                                |
| Esnaola et al.33           | 13              | USA          | Phase II     | BR     | n.s.             | Mixed                              | n.r.                                |
| Kim et al.34               | 62              | USA          | Phase II     | R+BR   | n.s.             | CRT                                | 63                                 |
| O’Reilly et al.35          | 38              | USA          | Phase II     | R      | n.s.             | CT                                 | 96                                 |
| Shaib et al.36             | 13              | USA          | Phase I      | BR     | n.s.             | CRT                                | n.r.                                |
| Calvo et al.37             | 15              | Spain        | Prospective  | R      | n.s.             | CRT                                | n.r.                                |
| Ohigashi et al.38          | 38              | Korea        | Prospective  | BR     | n.s.             | CRT                                | 100                               |
| Katz et al.39              | 22              | USA          | Prospective  | BR     | 0                | CRT                                | 67                                 |
| Oh et al.40                | 38              | Korea        | Prospective  | BR     | n.s.             | CRT                                | 61                                 |
| Tzeng et al.41             | 141             | USA          | Prospective  | BR     | n.s.             | CRT                                | 7-8                                |
| Tzeng et al.42             | 115             | USA          | Prospective  | BR     | n.s.             | CRT                                | 100                               |
| Fuji et al.20              | 21              | Japan        | Prospective  | BR     | > 1              | CRT                                | 56                                 |
| Fuji et al.21              | 40              | Japan        | Prospective  | R      | > 1              | CRT                                | 56                                 |
| Ielpo et al.42             | 11              | Spain        | Prospective  | BR     | n.s.             | CT                                 | 100                               |
| Masui et al.43             | 18              | Japan        | Prospective  | BR     | > 1              | CT                                 | 95                                 |
| Takai et al.44             | 32              | Japan        | Retrospective| R      | n.s.             | CRT                                | n.r.                                |
| Barbier et al.22           | 88              | France       | Retrospective| R      | > 1              | CRT                                | n.r.                                |
| Patel et al.45             | 18              | USA          | Retrospective| BR     | 0                | CRT                                | n.r.                                |
| Papalevoza et al.23        | 144             | USA          | Retrospective| BR     | n.s.             | CRT                                | 32-9                               |
| Chuong et al.46            | 57              | USA          | Retrospective| BR     | 0                | CRT                                | 84                                 |
| Dholakia et al.47          | 50              | USA          | Retrospective| BR     | 0                | CRT                                | 42                                 |
| Boone et al.48             | 61              | USA          | Retrospective| BR     | n.s.             | CRT                                | n.r.                                |
| Rose et al.49              | 64              | USA          | Retrospective| BR     | > 1              | CT/CRT                             | 90                                 |
| Monigli et al.50           | 14              | USA          | Retrospective| BR     | n.s.             | CRT                                | n.r.                                |
| Sho et al.51               | 99              | Japan        | Retrospective| R+BR   | n.s.             | CT/CRT                             | 75                                 |
| Rashid et al.52            | 121             | USA          | Retrospective| BR     | 0                | CRT                                | n.r.                                |
| Hiromi et al.25            | 46              | Japan        | Retrospective| BR     | 0                | Mixed                              | 85                                 |
| Murakami et al.26          | 52              | Japan        | Retrospective| BR     | n.s.             | CT                                 | 79                                 |

*Definition of R0: > 1, more than 1 mm clearance from each margin; 0, no cancer cells along any margin. | Among patients who underwent resection of pancreatic cancer. R, resectable; n.r., not reported; n.s., not specified; CT, chemotherapy; CRT, chemoradiotherapy; BR, borderline resectable; prospective, prospective cohort study; retrospective, retrospective cohort study; BR-V, borderline resectable with venous involvement; BR-A, borderline resectable with arterial involvement.
prospective (12) cohort studies. The studies showed heterogeneity in treatment and potential bias in collecting data. A common risk of bias was the heterogeneity of neoadjuvant and adjuvant treatments within and between the studies. Furthermore, there was wide variation in the duration of follow-up; in eight studies the follow-up was shorter than 12 months. In addition, different criteria were used for resectability, although most studies used the NCCN guidelines.

Three RCTs were included, one27 of which randomized between neoadjuvant gemcitabine or gemcitabine combined with capcitabine in patients with resectable pancreatic cancer. The other two trials15,16 randomized between neoadjuvant chemoradiotherapy and upfront surgery, but both were terminated early owing to poor accrual.

Primary outcome

The weighted median overall survival by intention to treat was 18.8 months in the neoadjuvant group and 14.8 months in the upfront surgery group.

Upfront surgery

Twelve studies15–26 reported the median overall survival of 1746 patients undergoing upfront surgery for resectable or borderline resectable pancreatic cancer by intention to treat (Figs 2 and 3). Overall, 81.3 per cent of 1746 patients underwent resection, with an overall weighted median overall survival of 14.8 (range 11.6–25.3) months.

The weighted median overall survival of 819 patients with resectable pancreatic cancer was 17.7 (12–25.3) months15–19,21–23,25, compared with 12.8 (11.6–16.3) months for 927 patients with borderline resectable pancreatic cancer20,24–26 (Figs 2 and 3). In the largest (retrospective) study of Kato and colleagues24,6 3 of 624 patients (10.1 per cent) with borderline resectable pancreatic cancer also received neoadjuvant treatment and the median overall survival of these patients was not available separately. The outcome of the subgroup of patients who actually underwent resection was reported in seven16,18,22–26 of 12 studies; the weighted median overall survival was 15.0 months for these 1048 patients (not by intention to treat).

Neoadjuvant treatment

Thirty-five studies15,16,19–23,25–52 reported median overall survival after neoadjuvant treatment of 1738 patients with resectable or borderline resectable pancreatic cancer. The neoadjuvant regimens used are shown in Table 2. The weighted median overall survival was 18.8 (range 9.4–50.2) months after neoadjuvant treatment.

For the 18 studies15,16,19,21–23,27–32,34,35,37,44,48,51 that reported the median overall survival of 857 patients with resectable pancreatic cancer, the weighted median overall survival was 18.2 (10–50.2) months (Fig. 2). In the 21 studies20,25,26,32–14,36,38–45,45–52 reporting the median overall survival after neoadjuvant treatment in 881 patients with borderline resectable cancer, the weighted median overall survival was 19.2 (11–32) months (Fig. 3).

The outcome for the subgroup of patients who actually underwent resection was reported in 19

Table 3 Median overall survival, resection rate and R0 rate after upfront surgery reported in 12 studies

| Reference | No. of patients | Median age (years) | Median OS (months) | Resection rate, ITT (%) | R0 rate* (%) | Patients with positive lymph nodes (%)* |
|-----------|----------------|--------------------|------------------|------------------------|-------------|----------------------------------------|
| Casadei et al.15 | 20 | 67.5 | 19.5 | 75 | 33 | 87 |
| Golcher et al.16 | 33 | 65-1 | 14-4 | 70 | 70 | 57 |
| Bao et al.17 | 78 | 68† | 17-9 | 77 | 75 | 58 |
| Raptis et al.18 | 102 | 64‡ | 12 | 32-7 | n.r. | n.r. |
| Tzeng et al.19 | 52 | 61.9 | 25-3 | 92 | 81 | 81 |
| Fuji et al.20 | 71 | 63 | 13-1 | 70 | 40 | 92 |
| Fuji et al.21 | 233 | 67 | 23-5 | 87-6 | 70-1 | 71 |
| Barbier et al.22 | 85 | 64 | 17 | 79 | 67 | 64 |
| Papalezova et al.23 | 92 | 65† | 13 | 74 | 79 | 62 |
| Kato et al.24 | 624 | 63-8 | 12-6 | 86-4 | 65-9 | 57 |
| Hirono et al.25 | 331 | BR-V: n.r. | R: 20-9 | R: 89-5 | R: n.r. | |
| Murakami et al.26 | 25 | BR-A: 69§ | 11-6 | 92 | 17 | 78 |
| Total | 1746 | Range 61-9–69 | 14-8 | 81.3 (79-4, 83-1) | 66.9 (64-2, 69-6) | 64.8 (62-0, 67-5) |

Values in parentheses are 95 per cent confidence intervals. *Among patients who underwent resection of pancreatic cancer. †Mean age. ‡Including patients with unresectable pancreatic tumours, who were not reported separately. §Including patients who received neoadjuvant treatment. OS, overall survival; ITT, intention to treat; R, resectable; n.r., not reported; BR-V, borderline resectable with venous involvement; BR-A, borderline resectable with arterial involvement.
Table 4 Median overall survival, resection rate and R0 rate after neoadjuvant treatment reported in 35 studies

| Reference          | No. of patients | Median age (years) | Median OS (months) | Resection rate ITT (%) | R0 rate (%)* | Patients with positive lymph nodes (%)* |
|--------------------|-----------------|--------------------|--------------------|-------------------------|--------------|----------------------------------------|
| Palmer et al.27     | 50              | 66                 | 13.6               | 54                      | 74           | 56                                     |
| Casadei et al.15    | 18              | 71.5               | 22.4               | 61                      | 64           | 55                                     |
| Golcher et al.16    | 33              | 62.5               | 17.4               | 58                      | 90           | 32                                     |
| Evans et al.28      | 86              | 65.8               | 22.7               | 74                      | 89           | 38                                     |
| Heinrich et al.29   | 29              | 59                 | 26.5               | 89                      | 80           | 64                                     |
| Le Scodan et al.30  | 41              | 59.3               | 9.4                | 63                      | 81           | 50                                     |
| Turri et al.31      | 34              | 61.5†              | 15.5               | 50                      | 100          | 24                                     |
| Small et al.32      | 17              | 62‡                | R: 10.2            | R: 43                   | n.r.         | 0                                      |
| Esnola et al.33     | 13              | 60                 | 24.1               | 69                      | 92           | n.r.                                   |
| Kim et al.34        | 62              | 64‡                | R: 26.5            | R: 57                   | 85           | 44                                     |
| O’Reilly et al.35   | 38              | 73                 | 27.2               | 71                      | 74           | 67                                     |
| Shaib et al.36      | 13              | 64                 | 11                 | 62                      | n.r.         | 13                                     |
| Calvo et al.37      | 15              | 61                 | 10                 | 60                      | 78           | n.r.                                   |
| Ohigashi et al.38   | 38              | 66                 | 32                 | 82                      | 97           | 10                                     |
| Katz et al.39       | 22              | 64                 | 21.7               | 68                      | 93           | 33                                     |
| Oh et al.40         | 38              | 59                 | 21.2               | 61                      | 78           | 4                                      |
| Tzeng et al.41      | 141             | 63                 | 19.1               | 59.6                    | 91.7         | 48-8                                   |
| Tzeng et al.19      | 115             | 65.5               | 28                 | 82.6                    | 89.5         | 51.5                                   |
| Fuji et al.25       | 21              | 66                 | 29.1               | 86                      | 100          | 17                                     |
| Fuji et al.21       | 40              | 65                 | 24.9               | 90                      | 86           | 39                                     |
| Ielpo et al.52      | 11              | 61.8†              | 20                 | 73                      | 100          | n.r.                                   |
| Masui et al.43      | 18              | 63                 | 21.7               | 83                      | 87           | 33                                     |
| Takai et al.44      | 32              | 61.8               | 19.2               | 75                      | n.r.         | n.r.                                   |
| Barbier et al.22    | 88              | 65                 | 15                 | 43                      | 92           | 29                                     |
| Patel et al.45      | 18              | 67                 | 15.6               | 50                      | 89           | n.r.                                   |
| Papaleozza et al.23 | 144             | 64                 | 15                 | 53.0                    | 78.0         | 25                                     |
| Chuong et al.46     | 57              | 64‡                | 16.4               | 56                      | 97           | 34                                     |
| Dholakia et al.47   | 50              | 63.5               | 17.2               | 58                      | 93           | 28                                     |
| Boone et al.48      | 61              | 64‡                | R: 20              | R: 95                   | R: 86        | n.r.                                   |
| Rose et al.49       | 64              | 66                 | 23.6               | 48                      | 87           | 58                                     |
| Moningi et al.50    | 14              | 67.2‡              | 14.4               | 29                      | 100          | n.r.                                   |
| Sho et al.51        | 99              | R: 8-41            | R: 50.2            | R: 100                  | R: 98        | n.r.                                   |
| BR-V: 66-3‡         |                    | BR-V: 26-6         |                    | BR-V: 97                | BR-V: 87     |                                        |
| BR-A: 66-0‡         |                    | BR-A: 18           |                    | BR-A: 84                | BR-A: 81     |                                        |
| Rashid et al.52     | 121             | 67                 | 17                 | 45.5                    | 98.4         | 63-6                                   |
| Hirono et al.25     | 46              | 69½               | 18                 | 87                      | 80           | 78                                     |
| Murakami et al.26   | 52              | 67½               | 27.1               | 90                      | 72           | 72                                     |

Total 1738 Range 59–73 18-8 months 66-0 (63-7, 68-2) 86-8 (84-6, 88-7) 43-8 (40-6, 47-1) Values in parentheses are 95% per cent confidence intervals. *Among patients who underwent resection of pancreatic cancer. †Mean age; ‡Including patients with unresectable pancreatic tumours, who were not reported separately. §Including patients who received upfront surgery. OS, overall survival; ITT, intention to treat; R, resectable; n.r., not reported; BR, borderline resectable; BR-V, borderline resectable with venous involvement; BR-A, borderline resectable with arterial involvement.

Studies16,19,22,23-25—31,34,37,40,41,44,46,47,52, and the weighted median overall survival was 26.1 months for these 764 patients (not by intention to treat).

Neoadjuvant chemotherapy versus chemoradiotherapy
Of all studies including patients who received neoadjuvant treatment, six used chemotherapy alone, 24 used chemoradiotherapy, and five used neoadjuvant chemotherapy in some patients and chemoradiotherapy in others. The weighted median overall survival was 20.9 (range 13.6–27.2) months for patients who received chemotherapy alone26,27,29,35,42,43 and 17.8 (9.4–32) months15,16,19–23,28,30–32,34,36–41,44–47,50,52 for chemoradiotherapy alone. Because of the heterogeneity between radiation dose and chemotherapy schedules, subset analyses should be interpreted with caution.

© 2018 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd.
Secondary outcomes

Resection rate and R0 rate

The overall resection rate was lower in patients who had neoadjuvant treatment than in those who had upfront surgery (66·0 versus 81·3 per cent; \( P < 0·001 \)).

After upfront surgery, the resection rate in all 1746 patients was 81·3 (95 per cent c.i. 79·4 to 81·3) (range 32·7–92) per cent. For patients with resectable pancreatic cancer, the resection rate was 76·8 (95 per cent c.i. 73·8 to 79·7) per cent, compared with 85·3 (82·9 to 87·5) per cent for those with borderline resectable pancreatic cancer (\( P < 0·001 \)).

For patients who received neoadjuvant treatment, the resection rate was reported in 35 studies\(^{15,16,20–23,25–52} \) and was 66·0 (95 per cent c.i. 63·7 to 68·2) (range 29–100) per cent. For patients with resectable pancreatic cancer, the resection rate was 67·0 (95 per cent c.i. 63·7 to 70·1) per cent, compared with 65·0 (61·8 to 68·2) per cent for those with borderline resectable pancreatic cancer (\( P = 0·418 \)).

The resection rate for patients in the neoadjuvant group who underwent an exploratory laparotomy was 91·2 per cent.

The R0 resection rate (only for patients who underwent resection) was higher in patients who had neoadjuvant treatment (86·8 versus 66·9 per cent; \( P < 0·001 \)). The R0 resection rate was also higher with neoadjuvant treatment when the results were reported by intention to treat (58·0 versus 54·9 per cent; \( P = 0·088 \)). This difference is obviously smaller, because it is the resection rate multiplied by the R0 rate.

The R0 resection rate was reported in 11 studies\(^{15–17,19–26} \) after upfront surgery and was 66·9 (95 per cent c.i. 64·2 to 69·6) (range 17–81) per cent. After upfront surgery, the R0 resection rate was 71·4 per cent for patients with resectable pancreatic cancer, and 63·9 per cent for those with borderline resectable pancreatic cancer. For patients treated with neoadjuvant therapy who underwent exploratory laparotomy followed by resection, the R0 resection rate was 86·8 (95 per cent c.i. 84·6 to 88·7) (range 38·9–100) per cent. After neoadjuvant treatment, the R0 resection rate was 85·0 per cent among patients.
Upfront surgery versus neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer

with resectable pancreatic cancer and 88.6 per cent for those with borderline resectable cancer.

Pathological lymph node rate

The pathological lymph node rate was reported in 11 studies after upfront surgery and was 64.8 (95 per cent c.i. 62.0 to 67.5) per cent, compared with 43.8 (40.6 to 47.1) per cent after neoadjuvant treatment in 27 studies. This difference in pathological lymph node rates between the two groups was significant ($P < 0.001$).

Reasons for not performing surgery

Of the 35 neoadjuvant therapy studies, 29 reported the reason for not performing exploratory surgery. In total, 306 patients (17.8 per cent) did not proceed to exploratory surgery. Progression of disease (locally advanced or metastasis) was the most common reason for not undertaking exploratory surgery in 64.4 per cent of these patients. In total, 55 patients (18.0 per cent) could not undergo surgery because of severe side-effects or deterioration of performance after neoadjuvant treatment, representing 3.2 per cent of all patients starting neoadjuvant treatment. For the remaining patients there were other reasons, or the reason was not known. The reasons for not performing tumour resection during exploratory surgery were reported in 23 of the 35 studies (Table S4, supporting information). Resection was not undertaken in at least 532 patients (15.3 per cent of all 3484 included patients). The most common reason for this was distant metastasis in 42.5 per cent of these patients. Disease progression was the reason for not resecting the tumour in 25.6 per cent.

Toxicity

There was a wide range of reported toxicity of neoadjuvant treatment across studies. The most common reported adverse events were gastrointestinal (emesis, nausea and diarrhoea) and haematological (thrombopenia,
leucopenia). Toxicity of at least grade III was reported in 21 studies \cite{15,16,20,25,27,34,36,39,42,44,46,50}, with a rate of up to 64 per cent, involving mostly leucopenia, thrombocytopenia, nausea and fatigue. Katz and colleagues \cite{39} reported a grade III toxicity rate of 64 per cent, in a study in which FOLFIRINOX (leucovorin, 5-fluorouracil, irinotecan and oxaliplatin) chemotherapy was combined with radiotherapy at a dose of 50-4 Gy. Grade IV toxicity was reported in 13 studies, and consisted mostly of haematological adverse events.

**Discussion**

In this systematic review, median overall survival was 18-8 months after neoadjuvant treatment versus 14-8 months after upfront surgery of resectable or borderline pancreatic cancer in intention-to-treat analysis. The R0 resection rate and pathological lymph node rate were also improved in the neoadjuvant group. These results suggest the superiority of neoadjuvant treatment over upfront surgery. Previous studies \cite{13,53} reported outcomes of patients who actually underwent resection, rather than reporting by intention to treat, thus introducing a survival bias.

Median survival times for patients who actually underwent resection were 26-1 months in the neoadjuvant group and 15-0 months for upfront surgery in this review. This difference in median overall survival between the groups (11-1 months) is much bigger than the difference in the intention-to-treat analysis (4-0 months). Reporting by intention to treat reduces potential bias in treatment effect as not all patients proceed to surgery, and a large proportion of patients do not receive adjuvant chemotherapy owing to postoperative complications. Prospective phase II studies investigating the role of neoadjuvant treatment have to report on all patients included in the trial by intention to treat \cite{54}. Therefore, for a fair comparison, upfront surgery studies and observational studies of neoadjuvant treatment should also report by intention to treat.

In the present review, 17-8 per cent of patients who had neoadjuvant treatment did not undergo exploratory surgery. This selects out patients with an aggressive pancreatic cancer that would probably have progressed in a short time after surgery anyway, thus avoiding a potentially harmful operation. In the upfront surgery group, the resection rate for patients with borderline resectable pancreatic cancer was significantly higher than that for patients with resectable tumours (85-3 versus 76-8 per cent respectively). This is a counterintuitive finding, as one would expect the resection rate to be higher for resectable pancreatic cancer. There is no good explanation for this finding, but the different criteria being used worldwide for assessing resectability or suboptimal preoperative assessment on CT may play a role. Centralization of pancreatic surgery has led to increased resection rates \cite{55}, but this was not investigated here.

The R0 resection rate among patients actually undergoing tumour resection was significantly better in the neoadjuvant treatment group, which is in line with the hypothesis that neoadjuvant treatment provides higher R0 rates than surgery alone \cite{56}. The R0 resection rate after upfront surgery is comparable to rates of 29–81 per cent, depending on the R0 criteria being used, in recent large series of pancreatic cancer resection \cite{57,58}. The pathological lymph node rate was also significantly different between the upfront surgery and neoadjuvant treatment groups, which may be the result of the neoadjuvant treatment causing regression of lymph node metastases \cite{59}.

No difference in surgical morbidity and mortality has been reported in studies comparing neoadjuvant treatment with upfront surgery \cite{60,61}. A possible advantage of neoadjuvant radiation is the development of pancreatic fibrosis, which may be associated with reduced occurrence of pancreas fistula after resection \cite{60,61,63}. Adjuvant chemotherapy is the current standard of care after resection of pancreatic cancer \cite{1}, but this treatment is often not given, or not completed, owing to a prolonged complicated postoperative course, or the preference of the patient or doctor. Data from the Netherlands Cancer Registry \cite{64} revealed that only 54 per cent of all patients undergoing pancreaticoduodenectomy received adjuvant chemotherapy, because of toxicity, age and other factors. In the present review, the toxicity reported most frequently consisted of adverse gastrointestinal and haematological events. Overall, treatment-related toxicity was given as the reason for not proceeding to exploratory surgery in only 3-2 per cent of the 1723 patients who started neoadjuvant treatment.

Median overall survival varied widely across the studies, which may be explained by the different criteria used for resectability. Most studies used the NCCN or MD Anderson Cancer Center criteria for resectability \cite{65,66}, but some studies used neither of these. Objective definitions of resectability are critical for the conduct of clinical trials of neoadjuvant treatment. Another explanation for the heterogeneity may be the variation in neoadjuvant treatment regimens across studies. The difference in receipt of postoperative adjuvant treatment (68-6 per cent in the upfront surgery group versus 31 per cent in the neoadjuvant group) may in part be explained by the fact that these patients had already received part or all of their systemic therapy before surgery.

The expert consensus statement of the AHPBA \cite{67} indicates that neoadjuvant therapy provides a rational
alternative to an upfront surgery approach and could be considered in all patients with resectable pancreatic cancer. Evidence from RCTs is still lacking. The Dutch Pancreatic Cancer Group has just finished accrual of the multicentre randomized PREOPANC trial (EU Clinical Trials Register: 2012-003181-40) of neoadjuvant chemoradiotherapy versus upfront surgery. The hypothesis is that neoadjuvant chemoradiotherapy may result in an increase in R0 resection rate and overall survival in patients with resectable or borderline resectable pancreatic cancer. The trial has randomized the required 248 patients during a 4-year interval and the first results are expected in 2018. Five other randomized trials are ongoing in Germany, Switzerland and Norway to investigate the role of neoadjuvant treatment in resectable pancreatic cancer. Two previous RCTs from Italy and Germany were terminated early because of poor accrual.

Some limitations of the present systematic review must be taken into account. First, the quality of the included studies is moderate; the majority are retrospective studies, with high suspicion of bias. Only three studies were RCTs, and only two of these, with a total of 104 patients, randomized between upfront surgery and neoadjuvant treatment followed by surgery. Both these studies were terminated early. Owing to the clinical and methodological heterogeneity, no network analysis could be performed. Despite the limitations, the results provide the most reliable sur-

geneity, no network analysis could be performed. Despite

Acknowledgements

The authors thank L. Barbier, R. Casadei, H. Golcher, S. Helton, H. Kato, P. A. Lind, T. Masui, R. Neale, J. B. Rose and C. R. Shubert for providing more detailed information about their articles; and R. Hollman for providing the median OS figures. J.A.V. and M.G.B. received a grant (no. 2014–7244) from the Dutch Cancer Society for studies on pancreatic cancer.

Disclosure: The authors declare no conflict of interest.

References

1 Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM et al.; European Study Group for Pancreatic Carcinoma. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017; 389: 1011–1024.

2 Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W et al. CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial. J Clin Oncol 2017; 35: 3330–3337.

3 Shab Y, Davila J, Naumann C, El-Serag H. The impact of curative intent surgery on the survival of pancreatic cancer patients: a U.S. population-based study. Am J Gastroenterol 2007; 102: 1377–1382.

4 Shrikhande SV, Barreto SG. Surgery for pancreatic carcinoma: state of the art. Indian J Surg 2012; 74: 79–86.

5 Stessin AM, Meyer JE, Sherr DL. Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry. Int J Radiat Oncol Biol Phys 2008; 72: 1128–1133.

6 Dutch Institute for Clinical Auditing (DICA). Jaarrapportage 2014. http://www.clinicalaudit.nl [accessed 1 September 2017].

7 Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.

8 Oxford Centre for Evidence-Based Medicine. Critical Appraisal for Therapy Articles, 2005. http://www.cebm.net/critical-appraisal/ [accessed 1 September 2017].

9 Critical Appraisal Skills Programme. 11 Questions to Help You Make Sense of a Trial. Randomised Controlled Trials Checklist; 2013. http://www.casp-uk.net/#casp-tools-checklists/c18f8 [accessed 1 September 2017].

10 Critical Appraisal Skills Programme. 12 Questions to Help You Make Sense of Cohort Study. Cohort Study Checklist; 2013. http://www.casp-uk.net/#casp-tools-checklists/c18f8 [accessed 1 September 2017].

11 Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD et al.; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.

12 Oxford Centre for Evidence-Based Medicine, Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence. http://www.cebm.net/wp-content/uploads/2014/06/CEBM-Levels-of-Evidence-2.1.pdf [accessed 1 September 2017].

13 Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLos Med 2010; 7: e1000267.

14 UCSF Clinical & Translational Science Institute. Sample Size Calculator: Confidence Interval for a Proportion. http://www .sample-size.net/confidence-interval-proportion [accessed 1 September 2017].

15 Casadei R, Di Marco M, Ricci C, Santini D, Serra C, Calculli L et al. Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastrointest Surg 2015; 19: 1802–1812.
16 Golcher H, Brunner TB, Witzigmann H, Marti L, Bechstein WO, Bruns C et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol 2015; 191: 7–16.

17 Bao P, Potter D, Eisenberg DP, Lenzner D, Zeh HJ, Lee lli on behalf of BJS Society Ltd. © 2018 The Authors.

18 Raptis DA, Fessas C, Belasyse-Smith P, Kurzawinski TR. Clinical presentation and waiting time targets do not affect prognosis in patients with pancreatic cancer. *Surgery* 2010; 8: 239–246.

19 Tzeng CW, Tran Cao HS, Lee JE, Pisters PW, Varadhachary GR, Wolf RA et al. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. *J Gastrointest Surg* 2014; 18: 16–24.

20 Fuji T, Yamada S, Murotani K, Kanda M, Sugimoto H, Nakao A et al. Inverse probability of treatment weighting analysis of upfront surgery versus neoadjuvant chemoradiotherapy followed by surgery for borderline resectable adenocarcinoma with arterial abutment. *Medicine (Baltimore)* 2015; 94: e1647.

21 Fuji T, Sato S, Yamada S, Murotani K, Yanagimoto H, Takami H et al. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting. *J Gastroenterol* 2017; 52: 81–93.

22 Barbier L, Turrini O, Grégoire E, Viret F, Le Treut YP, Delpero JR. Pancreatic head resectable adenocarcinoma: preoperative chemoradiation improves local control but does not affect survival. *HPB (Oxford)* 2011; 13: 64–69.

23 Papalezova KT, Tyler DS, Blazer DG III, Clary BM, Czito BG, Hurwitz HI et al. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? *J Surg Oncol* 2012; 106: 111–118.

24 Kato H, Usubi M, Isaji S, Nagakawa T, Wada K, Unno M et al. Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: a multi-institutional survey by the Japanese Society of Pancreatic Surgery. *J Hepatobiliary Pancreat Sci* 2013; 20: 601–610.

25 Hirono S, Kawai M, Okada KI, Miyazawa M, Shimizu A, Kitahata Y et al. Treatment strategy for borderline resectable pancreatic cancer with radiographic artery involvement. *Pancancer* 2016; 45: 1438–1446.

26 Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Nakagawa N et al. Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact. *Cancer Chemother Pharmacol* 2017; 79: 37–47.

27 Palmer DH, Stocken DD, Hewitt H, Markham CE, Hassan AB, Johnson PJ et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. *Ann Surg Oncol* 2007; 14: 2088–2096.

28 Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. *J Clin Oncol* 2008; 26: 3496–3502.

29 Heinrich S, Pestalozzi BC, Schäfer M, Weber A, Bauerfeind P, Knuth A et al. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. *J Clin Oncol* 2008; 26: 2526–2531.

30 Le Scodan R, Mornex F, Girard N, Mercier G, Valette PJ, Ychou M et al. Neoadjuvant chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. *Ann Oncol* 2009; 20: 1387–1396.

31 Turrini O, Ychou M, Moureaux-Zabotto L, Rouanet P, Giovannini M, Moutardier V et al. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: new neoadjuvant regimen was safe and provided an interesting pathologic response. *Eur J Surg Oncol* 2010; 36: 987–992.

32 Small W Jr, Mulcahy MF, Rademaker A, Bentrem DJ, Benson AB, Weitner BB et al. Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer. *Int J Radiat Oncol Biol Phys* 2011; 80: 476–482.

33 Esnaola NF, Chaudhary UB, O’Brien P, Garrett-Mayer E, Camp ER, Thomas MB et al. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capcitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys* 2014; 88: 837–844.

34 Kim EJ, Ben-Josef E, Herman JM, Bekaii-Saab T, Dawson Gerdes H, Capanu M et al. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. *Cancer* 2013; 119: 2692–2700.

35 O’Reilly EM, Perelshteyn A, Jarnagin WR, Schattner M, Gerdes H, Capanu M et al. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. *Ann Surg Oncol* 2014; 21: 142–148.

36 Shaib WL, Hawk N, Cassidy RJ, Chen Z, Zhang C, Brutcher E et al. A phase 1 study of stereotactic body radiation therapy dose escalation for borderline resectable pancreatic cancer after modified FOLFIRINOX (NCT01446458). *Int J Radiat Oncol Biol Phys* 2016; 96: 296–303.

37 Calvo FA, Matute R, García-Sabrido JL, Gómez-Espi M, Martínez NE, Lozano MA et al. Neoadjuvant chemoradiation with tegafur in cancer of the pancreas: initial analysis of clinical tolerance and outcome. *Am J Clin Oncol* 2004; 27: 343–349.
Upfront surgery versus neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer

38 Ohigashi H, Ishikawa O, Eguchi H, Takahashi H, Gotoh K, Yamada T et al. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3 Pancreatic cancer. Am Surg Oncol 2009; 250: 88–95.

39 Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, Colliison E et al. Preoperative modified FOLIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg 2016; 151: e161137.

40 Oh TG, Chung MJ, Bang S, Park SW, Chung JB, Song SY et al. Validation of group B borderline resectable pancreatic cancer: retrospective analysis. Gut Liver 2014; 8: 557–562.

41 Tzeng CW, Balachandran A, Ahmad M, Lee JE, Krishman S, Wang H et al. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford) 2014; 16: 430–438.

42 Ielpo B, Duran H, Diaz E, Fabra I, Caruso R, Ferri V et al. Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma. Eur J Surg Oncol 2016; 42: 1394–1400.

43 Masui T, Doi R, Kawasaki Y, Sato A, Nakano K, Itou T et al. Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors. Surg Today 2016; 46: 1282–1289.

44 Takai S, Sato S, Yanagimoto H, Toyokawa H, Takahashi K, Terakawa N et al. Neoadjuvant chemoradiation in patients with potentially resectable pancreatic cancer. Pancreas 2008; 36: e26–e32.

45 Patel M, Hoffe S, Malafa M, Hodul P, Klapman J, Centeno B et al. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol 2011; 104: 155–161.

46 Chuong MD, Springett GM, Freilich JM, Park CK, Weber JM, Mellon EA et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys 2013; 86: 516–522.

47 Dholakia AS, Hacker-Prietz A, Wild AT, Raman SP, Wood LD, Huang P et al. Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor–vessel relationships. J Radiat Oncol 2013; 2: 413–425.

48 Boone BA, Steve J, Zenati MS, Hogg ME, Singhi AD, Bartlett DL et al. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann Surg Oncol 2014; 21: 4351–4358.

49 Rose JB, Rocha FG, Alseidi A, Biehl T, Moonka R, Ryan JA et al. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Ann Surg Oncol 2014; 21: 1530–1537.

50 Moningi S, Dholakia AS, Raman SP, Blackford A, Cameron JL, Le DT et al. The role of stereotactic body radiation therapy for pancreatic cancer: a single-institution experience. Ann Surg Oncol 2015; 22: 2352–2358.

51 Sho M, Akahori T, Tanaka T, Kinoshita S, Nagai M, Tamamoto T et al. Importance of resectability status in neoadjuvant treatment for pancreatic cancer. J Hepatobiliary Pancreat Sci 2015; 22: 563–570.

52 Rashid OM, Pimiento JM, Gamenthaler AW, Nguyen P, Ha TT, Hutchinson T et al. Outcomes of a clinical pathway for borderline resectable pancreatic cancer. Ann Surg Oncol 2015; 23: 1371–1379.

53 Laurencé JM, Tran PD, Morarji K, Eslick GD, Lam VW, Sandroussis C. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg 2011; 15: 2059–2069.

54 Gupta SK. Intention-to-treat concept: a review. Perspect Clin Res 2011; 2: 109–112.

55 Gooiker GA, Lemmens VE, Besselink MG, Busch OR, Bonsing BA, Molenaar IQ et al. Impact of centralization of pancreatic cancer surgery on resection rates and survival. Br J Surg 2014; 101: 1000–1005.

56 Chua TC, Saxena A. Preoperative chemoradiation followed by surgical resection for resectable pancreatic cancer: a review of current results. Surg Oncol 2011; 20: e161–e168.

57 Howard TJ, Krug JE, Yu J, Zyromski NJ, Schmidt CM, Jacobson LE et al. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer. J Gastrointest Surg 2006; 10: 1338–1345.

58 Chardasegaram MD, Goldstein D, Simes J, Gebski V, Kench JG, Gill AJ et al. Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. Br J Surg 2015; 102: 1459–1472.

59 Roland CL, Yang AD, Katz MH, Chatterjee D, Wang H, Lin H et al. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Ann Surg Oncol 2015; 22: 1168–1175.

60 Cooper AB, Parmar AD, Riall TS, Hall BL, Katz MH, Aloia TA et al. Does the use of neoadjuvant therapy for pancreatic adenocarcinoma increase postoperative morbidity and mortality rates? J Gastrointest Surg 2015; 19: 80–86.

61 Denho JW, Bruno ML, Cloyd JM, Prakash L, Lee JE, Kim M et al. Preoperative chemoradiation for pancreatic adenocarcinoma does not increase 90-day postoperative morbidity or mortality. J Gastrointest Surg 2016; 20: 1975–1985.

62 Araujo RL, Gaujoux S, Huguet F, Gonen M, D'Angelica MI, DeMatteo RP et al. Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-matched analysis. HPB (Oxford) 2013; 15: 574–580.

63 Ishikawa O, Ohigashi H, Imaoka S, Teshima T, Inoue T, Sasaki Y et al. Concomitant benefit of preoperative...
irradiation in preventing pancreas fistula formation after pancreatoduodenectomy. *Arch Surg* 1991; **126**: 885–889.

64 Bakens MJ, van der Geest LG, van Putten M, van Laarhoven HW, Greemers GJ, Besselink MG *et al.* The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide population-based analysis. *Cancer Med* 2016; **5**: 2825–2831.

65 National Comprehensive Cancer Network. NCCN Guideline: Pancreatic Adenocarcinoma. Version 2.2016. http://www.trikobe.org/nccn/guideline/pancreas/english/pancreatic.pdf [accessed 1 September 2017].

66 Katz MH, Marsh R, Herman JM, Shi Q, Collison E, Venook AP *et al.* Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. *Ann Surg Oncol* 2013; **20**: 2787–2795.

67 Abrams RA, Lowy AM, O’Reilly EM, Wolff RA, Picozzi VJ, Pisters PW. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. *Ann Surg Oncol* 2009; **16**: 1751–1756.

68 Versteijne E, van Eijck CH, Punt CJ, Suker M, Zwinderman AH, Dohmen MA *et al.; Dutch Pancreatic Cancer Group (DPCG). Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. *Trials* 2016; **17**: 127.

69 Tachezy M, Gebauer F, Petersen C, Arnold D, Trepel M, Wegscheider K *et al.* Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA – a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749). *BMC Cancer* 2014; **14**: 411.

70 Heinrich S, Pestalozzi B, Lesurtel M, Berrevoet F, Laurent S, Delpero JR *et al.* Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). *BMC Cancer* 2011; **11**: 346.

71 Entrich TJ, Berger AW, Muche R, Lutz MP, Prasnikar N, Uhl W *et al.* NEOAX: neoadjuvant plus adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer – a phase II study of the AIO Pancreatic Cancer Group. *J Clin Oncol* 2014; **32**(Suppl 15): tps4158.

72 Hozaeel W, Paulik C, Homann N, Luley K, Kraus TW, Trojan J *et al.* Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: the NEPAFOX trial. *J Clin Oncol* 2015; **33**(Suppl 15): tps4152.

73 Labori KJ, Lassen K, Hoem D, Gronbech JE, Soreide JA, Mortensen K *et al.* Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial – 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial. *BMC Surg* 2017; **17**: 94.

Supporting information
Additional supporting information can be found online in the Supporting Information section at the end of the article.

Editor’s comments
Pancreas cancer is a systemic disease, so improved control must come from a systemic approach to management. At the time of writing, several centres have already adopted liberal use of neoadjuvant chemotherapy in patients with resectable pancreatic cancer. In contrast, national guidelines in the UK and elsewhere discourage neoadjuvant chemotherapy outside clinical trials. In the current meta-analysis, and in a recent phase II trial the toxicity was tolerable, but standard chemotherapy regimens have changed, which may alter safety and efficacy. Nonetheless, with such poor long-term outcome in pancreas cancer, present research does suggest that neoadjuvant chemotherapy is associated with better outcomes. Whether this simply reflects better selection of biological winners, or a genuinely improved disease control remains to be demonstrated in ongoing randomized clinical trials.

K. Søreide
Editor, BJS

Reference
1 Reni M, Balzano G, Zanon S, Zerbi A, Rimassa L, Castoldi R *et al.* Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. *Lancet Gastroenterol Hepatol* 2018 Apr 3. pii: S2468-1253(18)30081-5. doi: 10.1016/S2468-1253(18)30081-5.